BiotechTube
TrimGen

TrimGen

Sparks, United States· Est.
trimgen.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $12.5M

Overview

TrimGen is a U.S.-based developer and provider of molecular diagnostic products focused on genetic mutation analysis. The company's proprietary Shifted Termination Assay (STA) technology enables rapid, sensitive, and cost-effective detection of key mutations in hematopoietic cancers and for pharmacogenetic applications. Its product portfolio targets clinical research and early disease detection, offering an alternative to more expensive and time-consuming methods like NGS and Sanger sequencing. As a private company, TrimGen serves a global customer base of biomedical laboratories.

OncologyPharmacogenetics

Technology Platform

Shifted Termination Assay (STA) - a patented primer extension and fragment analysis method for multiplex mutation detection with high sensitivity (1-2%) and sequencing-like accuracy, using capillary electrophoresis for readout.

Funding History

2
Total raised:$12.5M
Series A$10M
Seed$2.5M

Opportunities

The growing need for rapid, cost-effective mutation profiling in hematologic cancers and pharmacogenetics creates a durable niche, especially in labs where NGS is too costly or slow for routine targeted testing.
The high sensitivity of STA technology also positions it well for applications like minimal residual disease monitoring, which requires detection of low-level mutations.

Risk Factors

The primary risk is technological obsolescence due to the continuous advancement and cost reduction of Next-Generation Sequencing, which could make targeted panels less attractive.
Competition from larger diagnostic companies offering PCR- and NGS-based kits on integrated platforms also poses a significant market threat.

Competitive Landscape

TrimGen competes in the targeted mutation detection space against large diagnostic firms (e.g., Qiagen, Roche, Thermo Fisher) offering PCR-based kits and NGS panels, as well as specialized companies using digital PCR or other technologies. Its key differentiators are the STA platform's claimed combination of sensitivity, speed, multiplexing, and low cost per test compared to alternatives.

More companies in United States →